Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab
International Journal of Clinical Oncology · 2024-10 · 29 (10) · 1528-1537
DOI: 10.1007/s10147-024-02593-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 24.07.2024. Verfasst von Takayuki Nakayama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan. Hauptthemen laut MEDLINE: Ipilimumab, Carcinoma, Renal Cell, Nivolumab, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Saitama Medical University.
Abstract (Originalsprache)
BACKGROUND: A useful biomarker for the efficacy of immune checkpoint inhibitors (ICIs) in advanced renal cell carcinoma (RCC) has not yet been established. This study aims to investigate whether inflammatory markers are associated with the efficacy of nivolumab plus ipilimumab therapy before and during treatment. METHODS: Data from patients with advanced clear cell RCC who received a combination treatment of nivolumab plus ipilimumab were retrospectively analyzed. The neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) levels were assessed at baseline and 3, 6, and 9 weeks after treatment initiation. The correlation between these inflammatory markers and the patient's prognosis was investigated. RESULTS: Eighty-four patients were identified. The multivariate analysis identified NLR at week 3, CRP at week 6, and NLR and CRP at week 9 as the consistent predictor associated with poor overall survival (OS) at each time point. The survival analysis and receiver operating characteristic (ROC) curve analysis revealed that an NLR of ≥ 2.4 at week 3, CRP of ≥ 1.4 mg/dL at week 6, and NLR of ≥ 4.8 and CRP of ≥ 1.0 mg/dL at week 9 were associated with worse OS (hazard ratios (HR) = 5.70, P = 0.008, HR = 3.23, P = 0.004, HR = 7.38, P < 0.001 and HR = 3.55, P = 0.002). CONCLUSIONS: Both NLR and CRP were considered useful biomarkers for understanding the prognosis during nivolumab plus ipilimumab therapy. Furthermore, an NLR of ≥ 4.8 and CRP of ≥ 1.0 mg/dL at week 9 are helpful in reconsidering treatment continuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan.
- Musashinno Study Group, Saitama, Japan.
- Department of Urology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan. takeuro@saitama-med.ac.jp.
- Musashinno Study Group, Saitama, Japan. takeuro@saitama-med.ac.jp.
- Department of Urology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
- Department of Uro-Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
Förderung
- Saitama Medical University
Zitieren
APA
Nakayama, T., Takeshita, H., Kagawa, M., Washino, S., Shirotake, S., Miura, Y., Hyodo, Y., Izumi, K., Inoue, M., Matsuoka, Y., Miyagawa, T., Oyama, M., Saito, K., & Kawakami, S. (2024). Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab. International Journal of Clinical Oncology, 29(10), 1528-1537. https://doi.org/10.1007/s10147-024-02593-1
Vancouver
Nakayama T, Takeshita H, Kagawa M, Washino S, Shirotake S, Miura Y, et al. Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab. International Journal of Clinical Oncology. 2024;29(10):1528-1537. doi:10.1007/s10147-024-02593-1
BibTeX
@article{Nakayama2024,
author = {Nakayama, Takayuki and Takeshita, Hideki and Kagawa, Makoto and Washino, Satoshi and Shirotake, Suguru and Miura, Yuji and Hyodo, Yoji and Izumi, Keita and Inoue, Masaharu and Matsuoka, Yoh and Miyagawa, Tomoaki and Oyama, Masafumi and Saito, Kazutaka and Kawakami, Satoru},
title = {Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab},
journal = {International Journal of Clinical Oncology},
year = {2024},
volume = {29},
number = {10},
pages = {1528--1537},
doi = {10.1007/s10147-024-02593-1}
}
EUVIMED